Peptomyc Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 18

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $29M

  • Investors
  • 12

Peptomyc General Information

Description

Developer of cell-penetrating peptide (CPP) therapeutics intended to treat cancer. The company's therapeutics target the Myc oncogene, a central function in cancer cell survival, that lets cancer cells divide and survive treatment for the treatment of certain cancers of the lung and breast, as well as against the brain tumor, enabling physicians and doctors to improve their chances of their patient's survival.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • C/Natzaret, 115-117
  • Centre Cellex
  • 08035 Barcelona
  • Spain
+34 932 00 00 00

Peptomyc Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Peptomyc Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series C) 01-Nov-2021 $29M 000.00 Completed Clinical Trials - Phase 1
11. Grant 29-Oct-2021 00000 000.00 Completed Clinical Trials - Phase 1
10. Later Stage VC (Series B) 16-Dec-2020 00.000 000.00 Completed Clinical Trials - Phase 1
9. Grant 01-Jun-2020 00.000 000.00 Completed Pre-Clinical Trials
8. Later Stage VC 29-May-2020 00.000 000.00 000.00 Completed Pre-Clinical Trials
7. Grant 01-Mar-2019 00000 00.000 Completed Pre-Clinical Trials
6. Grant 09-Jan-2019 00.000 00.000 Completed Pre-Clinical Trials
5. Accelerator/Incubator 12-Jun-2018 00.000 Completed Pre-Clinical Trials
4. Grant 19-Mar-2018 $6.16K $6.11M Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 06-Sep-2017 $4.97M $6.11M 000.00 Completed Pre-Clinical Trials
To view Peptomyc’s complete valuation and funding history, request access »

Peptomyc Executive Team (4)

Name Title Board Seat Contact Info
Laura Soucek Ph.D Co-Founder, Chief Executive Officer & Board Member
Jörg Klumbis Chief Financial Officer
Marie-Eve Beaulieu Ph.D Co-Founder, Chief Scientific Officer & Board Member
Manuela Niewel MD Chief Medical Officer
To view Peptomyc’s complete executive team members history, request access »

Peptomyc Board Members (8)

Name Representing Role Since
Edoardo Negroni AurorA-TT Board Member 000 0000
Giacomo di Nepi Self Chairman of the Board 000 0000
Laura Soucek Ph.D Peptomyc Co-Founder, Chief Executive Officer & Board Member 000 0000
Luís Pareras Ph.D Healthequity (Spain) Board Member 000 0000
Marie-Eve Beaulieu Ph.D Peptomyc Co-Founder, Chief Scientific Officer & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Peptomyc Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Peptomyc Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Angel Business Club Venture Capital Minority 000 0000 000000 0
VHIO Corporation Minority 000 0000 000000 0
AurorA-TT Venture Capital Minority 000 0000 000000 0
Empresa Nacional de Innovación Venture Capital Minority 000 0000 000000 0
Emprendedor XXI Government 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »